PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma | Zendy

Paul Nghiem | Zendy; Shailender Bhatia | Zendy; Evan J. Lipson | Zendy; Ragini R. Kudchadkar | Zendy; Natalie Miller | Zendy; Lakshmanan Annamalai | Zendy; Sneha Berry | Zendy; Elliot Chartash | Zendy; Adil Daud | Zendy; Steven P. Fling | Zendy; Philip Friedlander | Zendy; Harriet M. Kluger | Zendy; Holbrook E. Kohrt | Zendy; Lisa Lundgren | Zendy; Kim Margolin | Zendy; Alan Mitchell | Zendy; Thomas Olencki | Zendy; Drew M. Pardoll | Zendy; Sunil Reddy | Zendy; Erica Shantha | Zendy; William H. Sharfman | Zendy; Elad Sharon | Zendy; Lynn Shemanski | Zendy; Michi M. Shinohara | Zendy; Joel Sunshine | Zendy; Janis M. Taube | Zendy; John A. Thompson | Zendy; Steven M. Townson | Zendy; Jennifer H. Yearley | Zendy; Suzanne L. Topalian | Zendy; Martin A. Cheever | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Author(s) -

Paul Nghiem,

Shailender Bhatia,

Evan J. Lipson,

Ragini R. Kudchadkar,

Natalie Miller,

Lakshmanan Annamalai,

Sneha Berry,

Elliot Chartash,

Adil Daud,

Steven P. Fling,

Philip Friedlander,

Harriet M. Kluger,

Holbrook E. Kohrt,

Lisa Lundgren,

Kim Margolin,

Alan Mitchell,

Thomas Olencki,

Drew M. Pardoll,

Sunil Reddy,

Erica Shantha,

William H. Sharfman,

Elad Sharon,

Lynn Shemanski,

Michi M. Shinohara,

Joel Sunshine,

Janis M. Taube,

John A. Thompson,

Steven M. Townson,

Jennifer H. Yearley,

Suzanne L. Topalian,

Martin A. Cheever

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1603702

Subject(s) - merkel cell polyomavirus , merkel cell carcinoma , pembrolizumab , medicine , merkel cell , response evaluation criteria in solid tumors , oncology , carcinoma , cancer , gastroenterology , chemotherapy , phases of clinical research , immunotherapy

Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research